Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTPRB | P23467 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 2/20 | 0.34 |
| ▸ | CTSE | P14091 | 2/20 | 0.34 |
| ▸ | PGC | P20142 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932982 | 1.00 | REN (0.41) | RENMEN1KMT2ABRD4JAK2 | |
| SCHEMBL2929143 | 0.88 | REN (0.44) | RENMEN1KMT2AJAK2JAK1 | |
| SCHEMBL2940903 | 0.88 | REN (0.44) | RENMEN1KMT2AJAK2JAK1 | |
| SCHEMBL2940901 | 0.88 | REN (0.44) | RENMEN1KMT2AJAK2JAK1 | |
| SCHEMBL2929146 | 0.88 | REN (0.44) | RENMEN1KMT2AJAK2JAK1 | |
| SCHEMBL2938369 | 0.86 | REN (0.41) | RENMEN1KMT2AJAK2JAK1 | |
| SCHEMBL2938366 | 0.86 | REN (0.41) | RENMEN1KMT2AJAK2JAK1 | |
| SCHEMBL2934778 | 0.84 | NR1D1 (0.43) | RENMEN1KMT2AJAK2JAK1 | |
| SCHEMBL2934779 | 0.84 | NR1D1 (0.43) | RENMEN1KMT2AJAK2JAK1 | |
| SCHEMBL3606442 | 0.83 | REN (0.44) | RENMEN1KMT2AJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | claimed |
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | BREITENSTEIN WERNER | 2010-04-08 | — | — | US | disclosed |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2010-03-25 | — | — | US | disclosed |
| EP-1836163-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | Novartis AG (CH) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006066896-A2 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087427-A1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | REN, ACE, PEPD | REN 1/4885MEN1 1437/4885KMT2A 3722/4885 |
| US-20100075960-A1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS | ABCB1, CYP3A5, CYP3A4 | REN 2127/4885MEN1 2423/4885KMT2A 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.